Lilly Licenses Deciphera Technology ... | October 13, 2008 Issue - Vol. 86 Issue 41 | Chemical & Engineering News
Volume 86 Issue 41 | p. 21 | Concentrates
Issue Date: October 13, 2008

Lilly Licenses Deciphera Technology ...

Department: Business

Eli Lilly & Co. has teamed with Lawrence, Kan.-based Deciphera Pharmaceuticals to discover and develop drugs that block B-Raf kinase, a protein commonly mutated in cancer. Deciphera will be tasked with discovering small molecules that target the "switch pocket," a region on the protein that controls its shape and activity. The pact covers four projects related to selective or multikinase inhibitors, with Lilly retaining the exclusive rights to any product developed. Deciphera gains an up-front payment, two years of research funding, and possibly $130 million per compound developed.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment